N@N

Mintz Levin Represents BG Medicine in Closing of Initial Public Offering

_{//stocks-investing.news-articles.net/content/201 .. icine-in-closing-of-initial-public-offering.html}
^{Published in Stocks and Investing on Thursday, February 10th 2011 at 10:05 GMT by Market Wire}  

BOSTON--([ BUSINESS WIRE ])--[ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. ] represented BG Medicine (NASDAQ: BGMD) in its initial public offering of 5,750,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions.

Based in Waltham, Massachusetts, BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers.

Representing BG Medicine in the IPO were Mintz Levin [ Corporate ] Members [ Bill Whelan ] and [ Scott Samuels ].

Lazard Capital Markets LLC acted as the sole bookrunning manager for the initial public offering, and Baird and Cowen and Company acted as co-managers.

With one of the largest life sciences practices in the United States, Mintz Levin has represented more than 400 life sciences clients since the industrya™s inception in the 1970s. It has been described by ChambersUSA as aa leading life sciences branda and is ranked in the top tier nationally by U. S. News and World Report/Best Law Firms. The firma™s life sciences clients include biotechnology, medical device, medical technology, healthcare IT, and pharmaceutical companies; venture capital firms and investment banks; and research institutes and institutions of higher education located throughout the U.S., Europe, Asia, and the Middle Eastin a broad range of transactional, regulatory, counseling, and intellectual property matters.

For more information, please visit [ www.mintz.com ].